Yunlong Cao COVID predictor

ABSTRACT

Confronted with the prospect of stopping work, Cao realized that the methods he had specialized in could be used to study the antibodies triggered by infection with SARS-CoV-2. Cao - who leads much of the COVID-19 work in Xie's group - started his pandemic efforts by screening people who had recovered from COVID-19 for antibodies that could be used in treatment. Working with a Chinese drug company, the group picked two of the most potent infection-blocking, or neutralizing, antibodies and began trialling them in people with COVID-19.